IFU



A34060-A-A (090495.0285) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

De Brabander et al.

Customer No.:

21003

Serial No.

10/790,266

Examiner

Not Yet

Assigned

March 1, 2004

Group Art Unit:

1625

For

Filed

SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND

DERIVATIVES THEREOF

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 16, 2004

Date of Deposit

Rochelle K. Seide, Ph.D

32,300

Patent Reg. No.

KMI

June 16, 2004

Signature

Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully request that the references listed in reverse chronological order in the attached PTO-Form 1449 be made of record in the United States Patent and

Trademark Office relating to the above referenced application.

In accordance with 37 C.F.R. §1.98(d), copies of the identified references are not required to be provided because they were previously cited by or submitted to the Patent Office in the prior applications. Applicants have identified the prior applications and rely upon such prior applications for an earlier filing date under 35 U.S.C. §§ 119 and 120. The present application is a continuation of U.S. Patent Application Serial No. 10/418,757, filed April 18, 2003, now U.S. Patent No. 6,734,209, which is a continuation of U.S. Patent Application Serial No. 09/922,372, filed August 3, 2001, now U.S. Patent No. 6,617,348, which claims benefit of U.S. Provisional Patent Application Serial No. 60/222,809, filed August 4, 2000 and U.S. Provisional Patent Application Serial No. 60/252,856, filed November 22, 2000.

Identification of the listed documents is not to be construed as an admission of the Applicants or attorneys for Applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

NY02:488104.1 2

A34060-A-A (090495.0285)

PATENT

Applicants believe there is no fee required for this timely submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

Rochelle K. Seide, Ph.D. PTO Reg. No. 32,300

30 Rockefeller Plaza 44th Floor New York, NY 10012-4498

Attorney for Applicants (212) 408-2500

Enclosure

NY02:488104.1

3

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

JUN 1 8 2004 Atty. Docket No.

(A34060-A-A (090495.0285)

Serial No. 10/790,266

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

App	licant	
D۵	Rrah	ande

De Brabander et al.

Filing Date
March 1, 2004

Group 1625

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.							Date	Name	Class	Subclass	Filing Date if Appropriate
	5	9	3	6	1	0	0	8/10/99	Fürstner et al.			

FOREIGN PATENT DOCUMENT

	Document No.							Date	Country	Class	SubClass	Trans Yes	lator No
	0	0	5	1	5	8	9	9 Aug. 2000	WIPO				
	9	9	0	5	1	3	6	4 Feb. 1999	WIPO				
	9	9	4	7	5	2	3	23 Sept. 1999	WIPO				

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, Beutler JA, McKee TC, Bowman BJ, Bowman EJ (2001). Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H ⁺)-ATPases. <i>J. Pharmacol. Exp. Ther.</i> 297(1):114-120.
	Jansen R, Kunze B, Reichenbach H, Höfle G (2000). Antibiotics from gliding bacteria, LXXXVI. Apicularen A and B, cytotoxic 10-membered lactones with a novel mechanism of action from <i>Chondromyces</i> species (Myxobacteria): isolation, structure elucidation, and biosynthesis. <i>Eur. J. Org. Chem.</i> 2000:913-919.
	Snider BB, Song F (2000). Synthesis of the N-((1E)-alkenyl)-(2Z,4Z)-heptadienamide side chain of salicylihalamide A and apicularens A and B. Org. Lett. 2(3):407-408.
	Ackermann L, Fürstner A, Weskamp T, Kohl FJ, Herrmann WA (1999). Ruthenium carbene complexes with imidazolin-2-ylidene ligands allow the formation of tetrasubstituted cycloalkenes by RCM. <i>Tet. Lett.</i> 40:4787-4790.
	Huang J, Stevens ED, Nolan SP, Petersen JL (1999). Olefin metathesis-active ruthenium complexes bearing a nucleophilic carbene ligand. J. Am. Chem. Soc. 121:2674-2678.

NY02:488108.1

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 2

•		1 age 2 01 2					
Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34060-A-A (090495.0285)	Serial No. 10/790,266					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant De Brabander et al.						
(Use several sheets if necessary)	Filing Date Group March 1, 2004 1625						
Scholl M, Trnka TM, Morgan JP, Grubruthenium-based olefin metathesis cata Lett. 40:2247-2250.							
cytostatic macrolides from Chondromy	Kunze B, Jansen R, Sasse F, Höfle G, Reichenbach H (1998). Apicularens A and B, n cytostatic macrolides from <i>Chondromyces</i> species (Myxobacteria): production, physico-chemi and biological properties. <i>J. Antibiot. (Tokyo)</i> 51(12):1075-1080.						
McKee TC, Galinis DL, Pannell LK, RJ, Boyd MR (1998). The lobatamid tunicates. J. Org. Chem. 63:7805-7810	es, novel cytotoxic macrolides						
Erickson KL, Beutler JA, Cardellina I	Erickson KL, Beutler JA, Cardellina II JH, Boyd MR (1997). Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge <i>Haliclona</i> sp. <i>J. Org. Chem.</i> <u>62</u> :8188-8192.						
	Crider BP, Xie XS, Stone DK (1994). Bafilomycin inhibits proton flow through the H ⁺ channel of vacuolar proton pumps. <i>J. Biol. Chem.</i> 269(26):17379-17381.						
Mosmann T (1983). Rapid colorimetric proliferation and cytotoxicity assays. J.	c assay for cellular growth and survival: application to <i>I. Immunol. Meth.</i> 65(1-2):55-63.						
Still WC, Kahn M, Mitra A (1978). Rawith moderate resolution. J. Org. Chem		e for preparative separations					

NY02:488108.1

Examiner	Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.